Towards Scalable Immunotherapy: Automating TIL Manufacturing for GBM
- Glioblastoma multiforme (GBM) surgical aspirates provide a viable and accessible source of TILs
- The CliniMACS Prodigy® Tumor Reactive T Cell System enables fully automated, GMP-compliant manufacturing of clinical-grade TILs
- CD137 selection enriches GBM-TIL with gene signatures correlated with tumor reactivity and enhanced tumor killing capacity